Table 3.
Multivariate analysis for relapse in patients who underwent myeloablative URD or HLA-identical sibling transplantation for AML, ALL, and CML
| Factors | Relative risk | 95% CI | P |
|---|---|---|---|
| AML* | |||
| URD vs sib | 1.50 | 1.16-1.94 | .002 |
| Acute GVHD | 0.91 | 0.72-1.16 | .45 |
| Chronic GVHD | 0.75 | 0.56-0.99 | .046 |
| ALL† | |||
| URD vs sib | 0.95 | 0.68-1.33 | .78 |
| Acute GVHD | 0.78 | 0.57-1.07 | .13 |
| Chronic GVHD | 0.69 | 0.47-1.01 | .058 |
| CML‡ | |||
| URD vs sib | 0.91 | 0.65-1.27 | .56 |
| Acute GVHD | 0.84 | 0.62-1.13 | .25 |
| Chronic GVHD | 0.67 | 0.49-0.93 | .017 |
Relapse is increased in URD transplantations for AML but is similar between URD and sib for ALL and CML. The sib group was the reference group.
URD indicates unrelated donor; sib, HLA-identical sibling; AML, acute myeloid leukemia; ALL, acute lymphoid leukemia; CML, chronic myeloid leukemia, GVHD, graft-versus-host disease; CI, confidence interval; WBC, white blood cell; and CR1, first complete remission.
Model also adjusted for disease stage, WBC count, duration of CR1, and cytogenetics and stratified by graft type and Karnofsky score.
Model also adjusted for disease stage and stratified by graft type and Karnofsky score.
Model stratified by graft type, disease stage, and Karnofsky score.